Literature DB >> 25172213

Small amounts of functional ATP7A protein permit mild phenotype.

Lisbeth Birk Møller1.   

Abstract

Mutations in ATP7A lead to at least three allelic disorders: Menkes disease (MD), Occipital horn syndrome and X-linked distal motor neuropathy. These disorders are mainly seen in male individuals, but a few affected females have been described. More than 400 different mutations have been identified in the ATP7A gene. We have conducted several studies in the hope of uncovering the relationship between genotype and phenotype. We have examined the X-inactivation pattern in affected females, the effect of exon-deletions and--duplications, and splice-site mutations on the composition and amount of ATP7A transcript, and we have examined the structural location of missense mutations. The X-inactivation pattern did not fully explain the manifestation of MD in a small fraction of carriers. Most of the affected females had preferential inactivation of the X-chromosome with the normal ATP7A gene, but a few individuals exhibited preferential inactivation of the X-chromosome with the mutated ATP7A gene. The observed mild phenotype in some patients with mutations that effect the composition of the ATP7A transcript, seems to be explained by the presence of a small amount of normal ATP7A transcript. The location of missense mutations on structural models of the ATP7A protein suggests that affected conserved residues generally lead to a severe phenotype. The ATP7A protein traffics within the cells. At low copper levels, ATP7A locates to the Trans-Golgi Network (TGN) to load cuproenzymes with copper, whereas at higher concentrations, ATP7A shifts to the post-Golgi compartments or to the plasma membrane to export copper out of the cell. Impaired copper-regulation trafficking has been observed for ATP7A mutants, but its impact on the clinical outcome is not clear. The major problem in patients with MD seems to be insufficient amounts of copper in the brain. In fact, prenatal treatment of mottled mice as a model for human MD with a combination of chelator and copper, produces a slight increase in copper levels in the brain which perhaps leads to longer survival and more active behavior. In conclusion, small amounts of copper at the right location seem to relieve the symptoms.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Genotype–phenotype; Menkes disease; Mutation; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25172213     DOI: 10.1016/j.jtemb.2014.07.022

Source DB:  PubMed          Journal:  J Trace Elem Med Biol        ISSN: 0946-672X            Impact factor:   3.849


  4 in total

1.  Phenotypic convergence of Menkes and Wilson disease.

Authors:  Boglarka Bansagi; David Lewis-Smith; Endre Pal; Jennifer Duff; Helen Griffin; Angela Pyle; Juliane S Müller; Gabor Rudas; Zsuzsanna Aranyi; Hanns Lochmüller; Patrick F Chinnery; Rita Horvath
Journal:  Neurol Genet       Date:  2016-11-17

2.  Novel ATP7A gene mutation in a patient with Menkes disease.

Authors:  Gabriela Caicedo-Herrera; Estephania Candelo; Juan Pinilla; Andrés Vidal; Santiago Cruz; Harry Mauricio Pachajoa
Journal:  Appl Clin Genet       Date:  2018-11-22

3.  Occipital Horn Syndrome as a Result of Splice Site Mutations in ATP7A. No Activity of ATP7A Splice Variants Missing Exon 10 or Exon 15.

Authors:  Lisbeth Birk Møller; Mie Mogensen; David D Weaver; Per Amstrup Pedersen
Journal:  Front Mol Neurosci       Date:  2021-04-21       Impact factor: 5.639

4.  A novel nonsense ATP7A pathogenic variant in a family exhibiting a variable occipital horn syndrome phenotype.

Authors:  Maria Teresa Bonati; Federico Verde; Uros Hladnik; Paola Cattelan; Luca Campana; Chiara Castronovo; Nicola Ticozzi; Luca Maderna; Claudia Colombrita; Sergio Papa; Paolo Banfi; Vincenzo Silani
Journal:  Mol Genet Metab Rep       Date:  2017-07-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.